We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cirrhosis

News List

Changes to the Mavyret Product Label for Pediatrics americanpharmaceuticalreview
June 16, 2021
The FDA has approved Mavyret (glecaprevir and pibrentasvir) oral pellets (100mg/40mg) for the treatment of pediatric patients 3 to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection ...
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial americanpharmaceuticalreview
May 06, 2020
Lipocine announced that the U.S. Food & Drug Administration (FDA) has accepted the Company's Investigational New Drug application (IND) to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic potential of LPCN 1148.
Akero Expands NASH Trial to Include Cohort of Cirrhotic Patients americanpharmaceuticalreview
January 19, 2020
Akero Therapeutics announced the ongoing Phase 2a BALANCED study of AKR-001 is being expanded to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.